Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05373095
Other study ID # R01MH125746 - Phase II
Secondary ID R01MH125746
Status Recruiting
Phase N/A
First received
Last updated
Start date October 23, 2023
Est. completion date January 2025

Study information

Verified date March 2024
Source University of California, Berkeley
Contact Sandra I McCoy, PhD, MPH
Phone +15106420513
Email smccoy@berkeley.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This protocol describes an individually randomized trial that will include adult people living with HIV (PLHIV) currently receiving HIV care at one of two participating health facilities and identified as high risk for disengagement from care by a machine learning algorithm. Participants randomized to the control arm will receive standard of care HIV clinical services according to Tanzania's National Guidelines for the management of HIV. For those who meet clinic eligibility criteria for enhanced adherence counseling, which at the included study sites is when client's viral load reaches a detectable level (>1000 copies/ml), this includes the standard provision of three, once-monthly, 60-minute nurse-led individual, enhanced adherence counseling sessions, starting on the day of the result and for two months after. Intervention arm participants will receive the same standard HIV care services plus the offer of a cash transfer paired with visit attendance and attendance at each of the three adapted enhanced adherence counseling sessions (referred to as PKC sessions).


Description:

This protocol describes a 2-armed parallel individually randomized controlled trial for which 692 PLHIV who meet eligibility criteria, are currently accessing care at a participating health facility (Katoro Health Center, Geita Town Council Hospital, Geita Regional Referral Hospital, or Nyankumbu Health Center), and have provided informed consent to be part of the study will be randomized in a 1:1 ratio (n=346 PLHIV in each arm), stratified by site, to the control or intervention group. The investigators will use machine learning to finalize a predictive model based on routinely collected medical and pharmacy record data to identify and recruit PLHIV for participation at participating facilities who are at high-risk for disengaging from HIV care. Eligible and consenting participants randomized to the control arm will receive standard of care HIV clinical services according to Tanzania's National Guidelines for the Management of HIV. Criteria for enrollment into enhanced adherence counseling sessions includes when client's viral load reaches a detectable level (>1000 copies/ml). Enhanced adherence counseling includes the standard provision of three, once-monthly, 60-minute nurse-led individual, enhanced adherence counseling sessions, starting on the day of the result and for two months after. Counseling focuses on the meaning of viral loads and supportive, non-judgmental strategies for adherence and visit attendance. Sessions are conducted in an individual, 1:1 setting with a trained counselor who is on the clinical staff, or in a group setting with a trained counselor who is on the clinical staff. A minimum of three sessions are required. Eligible and consenting participants randomized to the intervention arm will receive the same standard HIV care services plus the offer of a cash transfer paired with visit attendance and attendance at each of the three adapted enhanced adherence counseling sessions (PKC sessions). The first payment will occur at enrollment; the next two cash transfers are payable upon visit attendance and attendance of the two remaining enhanced adherence counseling sessions. Due to the nature of the intervention, participants will not be blinded to intervention assignment. The primary endpoint is viral load suppression (<1000 copies/ml) at 12 months following study enrollment.


Recruitment information / eligibility

Status Recruiting
Enrollment 692
Est. completion date January 2025
Est. primary completion date December 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. PLHIV on ART; 2. Age 18 years or older; 3. Phone ownership OR consistent phone access; 4. Not already enrolled in/currently attending enhanced adherence counseling sessions at the facility 5. Living in Geita Region and intends to receive care at a study facility for the next 12 months; 6. Classified as "high-risk" for loss to follow-up (LTFU) from HIV care, and 7. Provides written informed consent for participation

Study Design


Related Conditions & MeSH terms

  • Acquired Immunodeficiency Syndrome
  • HIV (Human Immunodeficiency Virus)
  • HIV Infections

Intervention

Behavioral:
PKC (adapted adherence counseling) and Conditional Cash Transfers
The intervention includes up to 3 cash transfers of 22,500 Tanzanian Shillings (~$10) paired with attendance at each of the three adapted enhanced adherence counseling sessions (PKC sessions). The first cash transfer will occur at enrollment; the next two cash transfers are payable upon visit attendance and attendance of the two remaining PKC sessions. The cash transfers will include extra funds for transaction fees, typically <$1.

Locations

Country Name City State
Tanzania Geita Regional Referral Hospital Geita
Tanzania Geita Town Council Hospital Geita
Tanzania Nyankumbu Health Center Geita
Tanzania Katoro Health Center Katoro

Sponsors (6)

Lead Sponsor Collaborator
University of California, Berkeley Health for a Prosperous Nation, Management and Development for Health, Ministry of Health, Tanzania, National Institute of Mental Health (NIMH), Rasello

Country where clinical trial is conducted

Tanzania, 

Outcome

Type Measure Description Time frame Safety issue
Primary 12-Month Viral Suppression The proportion of people living with HIV (PLHIV) and on ART with suppressed HIV viral load ( <1000 copies/ml) at 12 months after study enrollment. 12 months
Secondary 6-month retention in care The proportion of people living with HIV (PLHIV) on ART at 6 months after study enrollment (PEPFAR considers those not retained on ART to include those who died, disengaged from care, stopped ART, or had no evidence of care for =28 days after a missed visit. Participants not found after exhaustive tracing efforts to rule out silent transfers will be classified as not retained on ART) 6 months
Secondary 12-month retention in care The proportion of people living with HIV (PLHIV) on ART at 12 months after study enrollment (PEPFAR considers those not retained on ART to include those who died, disengaged from care, stopped ART, or had no evidence of care for =28 days after a missed visit. Participants not found after exhaustive tracing efforts to rule out silent transfers will be classified as not retained on ART) 12 months
Secondary 12-month durable viral load Proportion with durable HIV viral suppression 12 months after enrollment: at least 2 viral load measurements taken from up to 6 months prior to study enrollment and up to and including 12 months following study enrollment and all are undetectable (<1000 copies/ml) will have met criteria for durable viral suppression at 12 months. 12 months
Secondary 12-month Appointment Attendance The proportion of scheduled visits that were completed during the 0-12 month period 12 months
Secondary 6-month Appointment Attendance The proportion of scheduled visits that were completed during the 0-6 month period 6 months
Secondary 12-month Mortality The cumulative incidence of mortality at 12 months after study enrollment 12 months
Secondary 6-month Predictive value positive (PVP) of machine learning algorithm Predictive value positive (PVP) of the machine learning algorithm in identifying PLHIV at-risk of disengagement from HIV care within 6 months 6 months
Secondary 12-month Predictive value positive (PVP) of machine learning algorithm Predictive value positive (PVP) of the machine learning algorithm in identifying PLHIV at-risk of disengagement from HIV care within 12 months 12 months
Secondary 6-month PVP of routine clinical criteria PVP of the routine clinical criteria (i.e. recent missed visit or detectable viral load, >1000 copies/ml) for identifying PLHIV at-risk of disengagement from HIV care within 6 months 6 months
Secondary 12-month PVP of routine clinical criteria PVP of the routine clinical criteria (i.e. recent missed visit or detectable viral load, >1000 copies/ml) for identifying PLHIV at-risk of disengagement from HIV care within 12 months 12 months
Secondary 6-month Predictive value negative (PVN) of the machine learning algorithm Predictive value negative (PVN) of the machine learning algorithm in identifying PLHIV not at-risk of disengagement from HIV care within 6 months 6 months
Secondary 12-month PVN of the machine learning algorithm PVN of the machine learning algorithm in identifying PLHIV not at-risk of disengagement from HIV care within 12 months 12 months
Secondary 6-month PVN of routine clinical criteria PVN of the routine clinical criteria for identifying PLHIV not at-risk of disengagement from HIV care within 6 months 6 months
Secondary 12-month PVN of routine clinical criteria PVN of the routine clinical criteria for identifying PLHIV not at-risk of disengagement from HIV care within 12 months 12 months
Secondary Enhanced Adherence Counseling Session Attendance Proportion of enhanced adherence counseling sessions completed among sessions scheduled 6 months
Secondary Viral Suppression with enhanced adherence counseling completion Proportion with HIV viral suppression after completion of enhanced adherence counseling sessions 6 months
Secondary 6-Month Viral Suppression (<1000 copies/ml) The proportion of people living with HIV (PLHIV) and on ART with suppressed HIV viral load ( <1000 copies/ml) at 6 months after study enrollment. 6 months
Secondary 6-Month Viral Suppression (<50 copies/ml) The proportion of people living with HIV (PLHIV) and on ART with suppressed HIV viral load ( <50 copies/ml) at 6 months after study enrollment. 6 months
Secondary 12-Month Viral Suppression (<50 copies/ml) The proportion of people living with HIV (PLHIV) and on ART with suppressed HIV viral load ( <50 copies/ml) at 12 months after study enrollment. 12 months
See also
  Status Clinical Trial Phase
Recruiting NCT04430257 - Pre-exposure Prophylaxis (PrEP) for Health N/A
Completed NCT03352219 - Reality Check: An HIV Risk Reduction Serial Drama N/A
Completed NCT03182738 - Video Information Provider for HIV-Associated Non-AIDS (VIP-HANA) Symptoms N/A
Active, not recruiting NCT04201353 - Optimizing the Efficiency and Implementation of Cash Transfers to Improve Adherence to Antiretroviral Therapy Phase II N/A
Completed NCT02969161 - Safe Generations Plus: Swaziland PMTCT LTF Study N/A
Completed NCT02027480 - Antiretroviral Therapy and Inflammatory and Coagulation Biomarkers: iMACS Study N/A
Completed NCT01992887 - Pre-ART Retention in Care in Tanzania N/A
Terminated NCT04499651 - Testing of a Navigation Intervention for Hepatitis C and HIV N/A
Active, not recruiting NCT05248100 - Rudi Kundini, Pamoja Kundini: Phase I N/A
Completed NCT00857298 - Effect of Diet-induced Weight Loss on HIV-associated Metabolic Syndrome N/A
Completed NCT02897141 - mVIP (Use of mHealth Technology for Supporting Symptom Management in Underserved Persons Living With HIV) N/A
Completed NCT01904994 - Link4Health: A Combination Strategy for Linkage and Retention, Swaziland N/A